Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 5, Issue 1, 2010, Pages 110-116

  Edelman, Martin J ^a   Belani, Chandra P ^b   Socinski, Mark A ^c   Ansari, Rafat H ^d   Obasaju, Coleman K ^e   Chen, Ruqin ^e   Monberg, Matthew J ^e   Treat, Joseph ^e  

^a UNIVERSITY OF MARYLAND   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d Northern Indiana Cancer Research Consortium   (United States)

^e Lilly USA   (United States)

Author keywords

Brain metastases; Nonplatinum doublets.; NSCLC; Phase III

Indexed keywords

CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG INDUCED HEADACHE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREMOR; VOMITING; WEIGHT REDUCTION;

EID: 76149126116     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181c59a3a     Document Type: Article

References (43)

1. Ries L, Eisner M, Kasary C, et al. SEER Cancer Statistics Review, 1975-2005. Bethesda, MD: National Cancer Institute, 2006.
2. Shepherd FA. Screening, diagnosis, and staging of lung cancer. Curr Opin Oncol 1993;5:310-322.
3. Walling J. Chemotherapy for advanced non-small-cell lung cancer. Respir Med 1994;88:649-657.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
5. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-smallcell lung cancer: how much benefit is enough? J Clin Oncol 1993;11: 1866-1872.
6. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994;106:861-865.
7. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21. (Pubitemid 23183916)
8. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008;59:1-11.
9. D'Addario G, Pintilie M, Leighl NB, Feld R, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-2936.
10. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002;16:325-338.
11. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37: 745-751.
12. Posner JB. Management of brain metastases. Rev Neurol (Paris) 1992; 148:477-487.
13. Wen PY, Loeffler JS. Management of brain metastases. Oncology (Williston Park) 1999;13:941-954, 957-961; discussion 961-962, 969.
14. Newman SJ, Hansen HH. Proceedings: frequency, diagnosis, and treatment of brain metastases in 247 consecutive patients with bronchogenic carcinoma. Cancer 1974;33:492-496.
15. Sorensen JB, Hansen HH, Hansen M, et al. Brain metastases in adeno- carcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988;6:1474-1480.
16. Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.
17. Sundstrom JT, Minn H, Lertola KK, et al. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med 1998; 30:296-1269
18. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322:494-500.
19. Zimm S, Wampler GL, Stablein D, et al. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981;48:384-394.
20. Ferrarese F, Baggio V, Zorat PL, et al. Treatment and prophylaxis for brain metastases from non-small cell lung cancer: whole brain radiation treatment versus stereotactic radiosurgery. Ann Oncol 2006; 17(Suppl 2):ii71-ii72.
21. Chang DB, Yang PC, Luh KT, et al. Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. Chest 1992;101:1293-1297.
22. Oh Y, Stewart DJ. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials. Oncology (Williston Park) 2008;22:168-178; discussion 178, 183, 188 passim.
23. Hochstenbag MM, Twijnstra A, Hofman P, et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung. Does it influence prognosis and treatment? Lung Cancer 2003;42:189-193.
24. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999;44:275-281.
25. Suzuki K, Yamamoto M, Hasegawa Y, et al. Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. Lung Cancer 2004;46:357-360.
26. Chang JE, Robins HI, Mehta MP. Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 2007;5:54-64.
27. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of nonsmall- cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001;12:59-67.
28. Treat J, Belani C, Edelman M, et al. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): update of the Alpha Oncology trial (A1-99002L). ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2005;23:Abstract 7025.
29. Treat J, Gonin R, Socinski MA, et al; for the Alpha Oncology Research Network. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol. 2009 Oct 15. [Epub ahead of print].
30. Fleming I, Cooper J, Henson D. AJCC Cancer Staging Manual, 5th Ed. Philadelphia: Lippincott-Raven, 1997.
31. Kaplan E, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatement in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216. (Pubitemid 30099779)
33. National Cancer Institute. NCI Common Toxicity Criteria, Version 2.0. Cancer Therapy Evaluation Program. Bethesda, MD: National Cancer Institute, 1999.
34. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556.
35. Cox D, Snell E. Analysis of Binary Data, 2nd Ed. London: Chapman and Hall, 1989.
36. Charloux A, Quoix E, Wolkove N, et al. The increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997;26:14-23.
37. Ott RJ, Brada M, Flower MA, et al. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991;27:1356-1361.
38. Stewart DJ, Mikhael NZ, Nair RC, et al. Platinum concentrations in human autopsy tumor samples. Am J Clin Oncol 1988;11:152-158.
39. Cotto C, Berille J, Souquet PJ, et al. A phase II trial of fotemustine and cisplatin in central nervous system metastases from non-small cell lung cancer. Eur J Cancer 1996;32A:69-71.
40. Minotti V, Crino L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998;20:93-98. (Pubitemid 28345190)
41. Lee J, Pisters K, Komaki R. Paclitaxel and carboplatin chemotherapy as a primary treatment of brain metastases in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 2000;19:Abstract 501.
42. Srivastava G, Rana V, Wallace S, et al. Risk of intracranial hemorrhage and cerebrovascular accidents in non-small cell lung cancer brain metastasis patients. J Thorac Oncol 2009;4:333-337.
43. Goodgame B, Govindan R. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials. Oncology (Williston Park). Available at: http://www.cancernetwork.com/lung-cancer/article/10165/1146761. Accessed February 25, 2009, 2008.